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Abstract: Whole-transcriptome analyses have revealed that a large proportion of the human genome
is transcribed in non-protein-coding transcripts, designated as long non-coding RNAs (lncRNAs).
Rather than being “transcriptional noise”, increasing evidence indicates that lncRNAs are key
players in the regulation of many biological processes, including transcription, post-translational
modification and inhibition and chromatin remodeling. Indeed, lncRNAs are widely dysregulated
in human cancers, including hepatocellular carcinoma (HCC). Functional studies are beginning
to provide insights into the role of oncogenic and tumor suppressive lncRNAs in the regulation
of cell proliferation and motility, as well as oncogenic and metastatic potential in HCC. A better
understanding of the molecular mechanisms and the complex network of interactions in which
lncRNAs are involved could reveal novel diagnostic and prognostic biomarkers. Crucially, it may
provide novel therapeutic opportunities to add to the currently limited number of therapeutic options
for HCC patients. In this review, we summarize the current status of the field, with a focus on the
best characterized dysregulated lncRNAs in HCC.
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1. Introduction
Hepatocellular carcinoma (HCC) is one of the several malignancies in which mortality has been
increasing, in particular, in Western populations [1]. HCCs typically arise on a background of cirrhosis
and are usually associated with chronic hepatitis B (HBV) or hepatitis C virus (HCV) infection, exposure
to aflatoxin B1, alcoholic liver disease, obesity or metabolic disorders. Treatment options for early-stage
HCC involve resection and/or liver transplantation. On the other hand, for late-stage patients, only
three systemic agents, namely sorafenib [2], regorafenib (both kinase inhibitors [3]), and nivolumab
(an immune checkpoint inhibitor) [4], have been approved. Novel therapeutic targets may improve
the dismal prognosis of late-stage HCC patients.
An increasing body of evidence suggests that the non-coding regions of DNA play fundamental
roles in the regulation of many biological processes, including physiological processes such as cell
growth and cell proliferation [5], cell migration [6], metabolism, and apoptosis [7]. Indeed, it is
now believed that ~70–80% of the human genome does not encode for proteins but is transcribed as
non-coding RNA (ncRNA) molecules [8,9]. A substantial portion of this “genomic dark matter” is long
non-coding RNA (lncRNA), defined as ncRNA greater than ~200 nucleotides in length, accounting
for 68% of RNA molecules [10]. lncRNA transcripts share some of the properties of protein-coding
transcripts. For instance, lncRNA transcription is regulated by histone modification and canonical
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spliceosome machinery [11–13]. Mechanistically, lncRNAs interact with transcription factors and may
variably guide them to [14] or prevent them from binding to their target genes [15]. They may also act
as enhancers by rearranging chromatin or may act as sponges to bind proteins or microRNAs [16–19].
Of their many roles, the best described is the recruitment of chromatin modifying complexes to specific
genomic regions [6,11,13,20–23] via chromosomal looping [24,25].
Given their multiple functions in transcriptional, post-transcriptional, and epigenetic regulation
of gene expression, they are emerging as new players in tumorigenesis. Indeed, increasing evidence
demonstrates that dysregulation of lncRNAs is involved in several pathological conditions, including
various types of cancer, such as those of the breasts, the lungs, prostate, and liver [26]. Two pan-cancer
studies using The Cancer Genome Atlas (TCGA) data have revealed that lncRNA expression is
tissue-, cell-type- and cancer-specific [10,27]. Of these two studies, one described 7942 lineage- or
cancer-associated lncRNAs across cancer types [10], while the other found that 60% of the dysregulated
lncRNAs is cancer type-specific [27].
Although there have been an increasing number of studies on lncRNAs in the past decade,
the contribution of lncRNAs to HCC development, metastasis, and recurrence remains largely
unknown. In the last years, many studies have been directed to the discovery and characterization
of the contribution of lncRNAs to carcinogenesis and their potential use as diagnostic markers
or therapeutic targets for HCC treatment. In this review, we will describe the biological roles of
lncRNAs, their mechanisms of action, and the lncRNAs dysregulated in HCC. We will further provide
an overview of the latest studies that are aimed at elucidating the potential uses of lncRNAs as
diagnostic/prognostic markers and as therapeutic targets in HCC.
2. LncRNAs: Characteristics and Subclassification
Among the many subclasses of ncRNA molecules, lncRNAs are defined as non-coding transcripts
that are more than ~200 nucleotides in length [28]. The most comprehensive characterization of
this class of non-coding RNA was carried out by the GENCODE consortium, which reported on
the extensive annotation of 14,880 human lncRNA species [12]. LncRNAs share many common
features with mRNA transcripts; they are both transcribed by RNA polymerase II, they both undergo
splice-processing and post-transcriptional modifications (5′-capping and polyadenylation), and they
share similar chromatin states. Unlike mRNAs, lncRNAs tend to be shorter, are expressed at lower
levels, and display fewer but longer exons [29]. Although lncRNAs show poor sequence conservation
among species, their peculiar secondary structures, mechanisms of action, and localization appear to be
highly conserved [30]. These features allow for lncRNAs to be classified according to several divergent
criteria [31]. lncRNA subcellular localization, for instance, provides valuable information related to
their functions and mechanisms of action. The known subcellular localization of lncRNAs based on
RNA sequencing data has been collated into the lncATLAS database [32]. In general, lncRNAs tend to
be more abundant in the nucleus [31], with some of them being reported to be chromatin-associated
RNAs (CARs) [23] and some others that are directly related to the formation of nuclear bodies,
such as NEAT1 and MALAT1 [33,34]. Single molecule RNA FISH analysis, revealed that even nuclear
localization can be further categorized in distinct nuclear patterns [35], with the presence of both bright
nuclear foci with distinct lncRNAs and single dispersed nuclear lncRNAs. Of note, some lncRNAs
have been reported to be enriched in the cytosol and to localize with ribosomes [36]. Interestingly,
lncRNAs have also been reported to be encoded in the small mitochondrial genome [37].
Despite the diverse features that are displayed by lncRNAs, as a general rule, they are broadly
classified according to their biogenesis and genomic positions in relation to protein-coding genes,
lncRNAs can be broadly classified into: (i) antisense RNAs or natural antisense transcripts (NATs);
(ii) bidirectional RNAs; (iii) long intergenic RNAs (lincRNAs); and (iv) sense intronic RNAs [12,38,39]
(Figure 1).
Int. J. Mol. Sci. 2018, 19, 682 3 of 25
Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  3 of 25 
 
 
Figure 1. Long non-coding RNA (LncRNA) classification in the context of different genomic locations. 
On the basis of genomic location and orientation to genes there are four major classes of lncRNAs. (a) 
Antisense lncRNAs are transcribed from the opposite strand of coding genes; (b) Bidirectional 
lncRNAs are transcribed from the opposite strand, in the opposite direction and within 1 kb of the 
promoter of coding genes; (c) Intergenic lncRNAs are transcribed in the genomic region between two 
coding genes and usually are located in enhancer regions acting in cis on the promoters of the 
downstream genes; and, (d) Sense-intronic lncRNAs are transcribed from the sense strand of an 
intronic region with no overlap of exonic sequence. Ex: exon. 
2.1. Antisense RNAs or Natural Antisense Transcripts (NATs) 
NATs are endogenous RNAs that partially or totally overlap transcripts originating from their 
opposite strand. Yelin et al., estimated that more than 8% of the predicted 40,000 human genes have 
an antisense partner [40]. A substantial portion of eukaryotic promoters may indeed be transcribed 
in both the sense and the antisense directions [41]. Sense and antisense transcripts are usually 
regulated in a coordinated way, such as that high levels of the sense transcript usually lead to high 
levels of the antisense transcript, and vice versa. 
2.2. Bidirectional RNAs 
Bidirectional RNAs are also known as promoter-associated non-coding RNAs (pancRNAs) [42]. 
Slightly different from NATs, bidirectional RNAs are transcribed in the opposite direction with 
respect to the protein coding gene, but are located within 1 kb from its promoter region [42–45]. An 
example of this class of lncRNA is Linc00441, the bidirectional transcribed lncRNA of the 
Retinoblastoma gene RB1. Linc00441 has recently been reported to be aberrantly upregulated and 
inversely correlated to RB1 expression in human HCC samples [46]. More specifically, Linc00441 has 
also been reported to epigenetically suppress RB1 expression in HCC by recruiting DNMT3A 
methyltransferase [46]. 
2.3. Long Intergenic RNAs (LincRNA) 
LincRNA refers to the class of non-coding RNAs that are transcribed from intergenic regions 
between two protein-coding genes [47]. The majority of lincRNAs are enhancer RNAs (eRNAs) thar 
are located in enhancer regions and usually act in cis by inducing chromatin modifications in the 
promoters of the downstream genes [24]. A classic example of eRNA is the HOXA transcript at the 
distal tip (HOTTIP), a lncRNA situated in the 5′ distal region of the HOXA locus [25]. As one of the 
Figure 1. Long non-coding RNA (LncRNA) classification in the context of different genomic locations.
On the basis of genomic location and orientation to genes there are four major classes of lncRNAs.
(a) Antisense lncRNAs are transcribed from the opposite strand of coding genes; (b) Bidirectional
lncRNAs are transcribed from the opposite strand, in the opposite direction and within 1 kb of the
promoter of coding genes; (c) Intergenic lncRNAs are transcribed in the genomic region between
two coding genes and usually are located in enhancer regions acting in cis on the promoters of the
downstream enes; and, (d) Sense-intro i lncRNAs are transcribed from the sense strand of an intronic
region with no overlap of exonic sequence. Ex: exon.
2.1. Antisense RNAs or Natural Antisense Transcripts (NATs)
NATs are endogenous RNAs that partially or totally overlap transcripts originating from their
opposite strand. Yelin et al., estimated that more than 8% of the predicted 40,000 human genes have an
antisense partner [40]. A substantial portion of eukaryotic promoters may indeed be transcribed in
both the sense and the antisense directions [41]. Sense and antisense transcripts are usually regulated
in a coordinated way, such as that high levels of the sense transcript usually lead to high levels of the
antisense transcript, and vice versa.
2.2. Bidirectional RNAs
Bidirectional RNAs are also known as promoter-associated non-coding RNAs (pancRNAs) [42].
Slightly different from NATs, bidirectional RNAs are transcribed in the opposite direction with respect
to the protein coding gene, but are located within 1 kb from its promoter region [42–45]. An example
of this class of lncRNA is Linc00441, the bidirectional transcribed lncRNA of the Retinoblastoma gene
RB1. Linc00441 has recently b en reported to be aberrantly upregulated and inversely correlated to
RB1 expression in human HCC samples [46]. More specifically, Linc00441 has also been reported to
epigenetically suppress RB1 expression in HCC by recruiting DNMT3A methyltransferase [46].
2.3. Long Intergenic RNAs (lincRNA)
LincRNA refers to the class of non-coding RNAs that are tr nscribed f om intergenic regions
between two protein-coding ge es [47]. The majority of lincRNAs are enhancer RNAs (eRNAs) that
are located in enhancer regions and usually act in cis by inducing chromatin modifications in the
promoters of the downstream genes [24]. A classic example of eRNA is the HOXA transcript at the
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distal tip (HOTTIP), a lncRNA situated in the 5′ distal region of the HOXA locus [25]. As one of the
best characterized lncRNAs implicated in HCC, HOTTIP will be extensively described in one of the
following sections.
2.4. Sense Intronic RNAs
Sense intronic RNAs are transcribed from the introns of protein-coding genes and do not overlap
exonic sequences. Examples of sense intronic RNAs are small nuclear-lncRNAs (sno-lncRNAs) and
circular intronic lncRNAs (circRNAs). Sno-lncRNAs are lncRNAs that are flanked by two small
nuclear RNAs (sno-RNAs) and thereby lack any 5′ and 3′ processing [48]. CircRNAs, instead, form a
peculiar class of lncRNA that undergoes a special splicing (back-splicing) thus resulting in chemically
circularized molecules [49].
3. LncRNAs: Mechanisms of Action
RNAs are very versatile molecules; they can interact with other nucleic acid molecules by simple
base pair coupling and they can interact with proteins by folding into three-dimensional (3D) structures
and generating complex recognition surfaces. RNAs are also dynamic; they can be both transcribed
and degraded rapidly [50]. The versatility and dynamic nature are particularly evident for lncRNAs
whose ability to bind both nucleic acids and proteins enables them to regulate gene expression on the
transcriptional, post-transcriptional, and protein levels (Figure 2).
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Figure 2. Mechanism of function of lncRNAs dysregulated in hepatocellular carcinoma (HCC). 
LncRNAs may act as sponges for miRNAs, bind transcripts or proteins and induce epigenetic 
modifications or chromatin remodeling. Their deregulation leads to hepatocellular carcinogenesis by 
regulating different cellular processes such as migration, proliferation, invasion, cell cycle, apoptosis 
and epithelial mesenchymal transition (EMT). Examples of the mechanisms of action of lncRNAs 
dysregulated in HCC are reported. See text for details. 
3.1. Transcriptional Regulation and Chromatin Modification 
One of the best described mechanisms of action of lncRNAs is their capacity to induce epigenetic 
modifications by acting as a scaffold for chromatin modification complexes. This discovery provided 
insight into the previously unresolved question on how chromatin modification complexes are able 
to act on the whole genome in a time-dependent and a cell-specific manner. Indeed, lncRNAs can 
Figure 2. Mechanism of function of lncRNAs dysregulated in hepatocellular carcinoma (HCC).
LncRNAs may act as sponges for miRNAs, bind transcripts or proteins and induce epigenetic
modifications or chromatin remodeling. Their deregulation leads to hepatocellular carcinogenesis by
regulating different cellular processes such as migration, proliferation, invasion, cell cycle, apoptosis
an epithelial mesenchymal transition (EMT). Examples of the mechanisms of action of lncRNAs
dysregulated in HCC are reported. See text for details.
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3.1. Transcriptional Regulation and Chromatin Modification
One of the best described mechanisms of action of lncRNAs is their capacity to induce epigenetic
modifications by acting as a scaffold for chromatin modification complexes. This discovery provided
insight into the previously unresolved question on how chromatin modification complexes are able to
act on the whole genome in a time-dependent and a cell-specific manner. Indeed, lncRNAs can guide
chromatin remodeling complexes to specific genomic regions, regulating gene expression either in cis
or in trans, as enhancers and mediators for long-range chromatin interactions [20,21].
The role of lncRNA as a scaffold for chromatin remodeling complexes was first described for
the HOX transcript antisense RNA (HOTAIR). HOTAIR was reported to interact with the Polycomb
repressive complex 2 (PRC2), thereby repressing the expression of the HOXD gene locus by inducing
histone methylation and heterochromatin formation [51]. The same mechanism has now been
demonstrated for other lncRNAs, such as XIST [52], the lncRNA that is responsible for X-chromosome
inactivation, and it appears to be a general mechanism by which lncRNAs regulate gene expression
during imprinting, development, cell differentiation, and disease [53,54].
Chromatin modification is not the only way through which lncRNAs modulate transcription.
NATs, for instance, are able to directly inhibit the transcription of their sense transcripts in cis by
competing for RNA polymerase II [55] or by forming an RNA-DNA triplex that prevents the binding of
the transcription initiation complex [15]. Additionally, lncRNAs can fold into secondary structures that
mimic DNA binding sites, further inhibiting the nuclear export of transcriptional factors by directly
interacting with and repressing their associated transport proteins [56].
3.2. Post-Transcriptional Regulation and Maintenance of mRNA Stability
On the post-transcriptional level, lncRNAs play a role in regulating mRNA splicing. For example,
NATs can form RNA-RNA duplexes which can mask splice sites [57]. Other lncRNAs, such as the
metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), have been reported to regulate
splicing by directly modulating the activity of Ser/Arg-domain rich splicing factors [58].
LncRNAs may also influence mRNA stability by acting as competing endogenous RNAs
(ceRNAs) [59–61] that compete for the binding of shared miRNAs. In particular, the circRNA subclass
almost exclusively acts as miRNA decoy [17]. An example is circMTO1 that has been recently described
to promote HCC cell proliferation and invasion by binding miR-9 and down-regulating p21 [62].
In general, miRNA sponging is a common mechanism among lncRNAs, owing to the presence of
miRNAs competing target sites in their sequences. When the lncRNA with the complementary
sequence becomes transcriptionally active, it competes for miRNA targeting and binding of RISC
complexes, thus resulting in increased parent gene expression [18]. Several examples have been
reported in HCC, such as the lncRNA highly upregulated in liver cancer (HULC) [16], MALAT1 [63],
and nuclear enriched abundant transcript 1 (NEAT1) [64]. LncRNAs may also help to destabilize
mRNA transcripts by activating a specific type of mRNA decay, called Staufen-mediated decay. This
is the case for Alu repeats-containing lncRNAs, which can bind Alu sequences in the 3’UTR of target
genes, thus mediating the binding of Staufen1 and the subsequent mRNA degradation [65].
3.3. Protein Activity Regulation and Scaffolding
Several lncRNAs have been reported to regulate cellular processes by direct binding to proteins,
including RNA-binding proteins (RBPs) and transcription factors [66]. For example, Gadd7 and
MALAT1 bind to and modulate the expression of RBP TDP43 [67], which is a protein that is implicated
in mRNA splicing, transport, and stability [68]. Moreover, in silico prediction suggested that the
HCC-associated lncRNAs HOTTIP, H19, HOTAIR, MALAT1, AIRN, MEG3, and uc002mb may interact
with the RBPs eIF4AIII, PTB, and FUS [69]. In addition, lncRNAs harbor several distinct domains,
each able to bind to distinct effector molecules, thus enabling them to serve as adaptors to bring
proteins into complexes [66]. Apart from the role that lncRNAs play in chromatin remodeling, they
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may also serve as scaffolds for nuclear domains [70]. One such example is NEAT1, which has been
implicated in the de novo assembly of the subnuclear organelles paraspeckles [71].
4. Widespread lncRNA Dysregulation in HCC
Significant effort has been made to examine the expression of lncRNAs and its relationship
with carcinogenesis. The use of lncRNA microarrays and next generation sequencing techniques has
allowed for researchers to perform genome-wide analyses to identify a large number of lncRNAs
aberrantly expressed in HCC tissue and may be involved in hepatocarcinogenesis.
Cui et al. [72] performed a comprehensive investigation into lncRNA expression profile in HCC
and matched non-tumor counterpart using two RNA sequencing datasets (including that of TCGA),
and two lncRNA microarray datasets. The authors identified 347 lncRNAs that were consistently up-
or down-regulated in at least two datasets [72]. They found that 31 and 41 lncRNA loci were located
in genomic regions with recurrent DNA gains or losses, respectively, suggesting that genomic copy
number alterations may be involved in the dysregulation of some lncRNAs in HCC. Furthermore, by
comparing lncRNA expression pattern in HCC with or without invasion and metastasis, they also
identified lncRNAs that may be involved in cancer cell metastasis and HCC recurrence [72].
Similar genome-wide lncRNA profiling studies carried out by other groups have invariably
pointed to the general conclusion of widespread lncRNA dysregulation in HCC. An RNA-sequencing
study of HBV-related HCC samples revealed a total of 1242 dysregulated lncRNA transcripts
(983 up-regulated and 259 down-regulated) [73]. In another study of 12 HCC tissues and paired
adjacent normal tissues, the authors identified 214 differentially expressed lncRNAs, among which 17
were further confirmed in 21 paired HCC and normal liver tissues via quantitative real-time PCR [74].
Finally, an RNA-sequencing analysis from 20 HCC patients recently identified 8603 novel dysregulated
lncRNAs, including 917 recurrently dysregulated lncRNAs that were associated with clinicopathologic
features [75]. Of particular interest was the observation that approximately 76% of the HCC-related
lncRNAs were not previously annotated by the MiTranscriptome [10] or GENCODE [76], suggesting
that at least some of the dysregulated lncRNAs might be HCC-specific [75].
4.1. Molecular and Functional Alterations of lncRNAs in HCC
Despite the huge number of lncRNAs described to be dysregulated in HCC by genome-wide
approaches, not many have been comprehensively characterized (Table 1 and S1).
The vast majority of them is reported to be up-regulated in HCC and have been shown to have an
oncogenic effect by promoting cell proliferation, invasion, metastasis formation, and/or angiogenesis.
Investigations into the expression of these oncogenic lncRNAs have found them to be positively
correlated with clinicopathological features of the patients. In this section, we will describe some of the
well-characterized lncRNAs dysregulated in HCC in detail, giving some examples of their molecular
mechanisms in cancer and their specific role in hepatocellular carcinogenesis. An extended list of the
lncRNAs, their dysregulation, and molecular functions in HCC can be found in Table S1.
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Table 1. LncRNAs dysregulated in HCC.
lncRNA Class Expression in HCC Effect on HCC Molecular Mechanism Reference
H19 intergenic downregulated/upregulated
Inhibits migration and invasion; associated
with HCC aggressiveness and poor outcome;
promotes cell growth
Recruits HnRNP U/PCAF/RNAPolII complex to activate
miR-200 family through histone acetylation;is involved in the
miR675/AKT/GSK-3beta/Cdc25A signaling pathway;
interacts with EZH2 and represses E-caderin expression
[77–79]
HEIH intergenic upregulated Promotes tumor progression and inhibitsG0/G1 cell cycle arrest Interacts with EZH2 and represses target genes [80,81]
HOTAIR intergenic upregulated
Promotes cell proliferation, viability,
invasion, migration and metastasis;
suppresses apoptosis
Regulates miR-331-3p/HER2, miR-1/FOXC1,
miR-218/BMI1/Ink4a/ARF, DDX5/PRC2, STAT3,
GLUT1/mTOR signaling pathways
[82–88]
HOTTIP intergenic upregulated Promotes cell proliferation, migration,tumorigenesis and metastasis Interacts with WDR5/MLL promoting H3K4me3 [89,90]
HULC intergenic upregulated
Promotes cell growth, proliferation, EMT,
migration, tumor progression, metastasis,
angiogenesis; modulates lipid metabolism
Regulates several signaling pathways including
miR-9/PPARA/ACSL1, miR-200a-3p/ZEB1,
miR-107/E2F1/SPHK1, miR-488/ADAM, mR186/HMGA2;
regulates the ubiquitin-mediated degradation of Sirt1
[91–98]
MALAT1 antisense upregulated Promotes cell invasion, migration, growth,motility and metastasis
Sponges miR-125b, miR-146b-5p, miR-204, miR-143-3p,
miR-195; regulates p53/DBC1 signaling pathway [63,99–101]
MEG3 intergenic downregulated Promotes proliferation and apoptosis Regulates p53 transcription [102–107]
NEAT1 intergenic upregulated Promotes tumorigenesis, EMT, cellproliferation, migration and metastasis
Regulates the miR-129-5p/VCP/IkB axis; sponges miR-613;
regulates STAT3 expression through miR-485; regulates
hnRNP A2 expression by sequestrating U2AF65; is involved
in paraspeckle formation
[108–112]
UCA1 intergenic upregulated
Promotes EMT; is associated with tumor size,
vascular invasion, TNM stage, metastasis
and postoperative survival
Activates ERK signaling pathway; regulates
SNAIL2 expression [113–116]
EMT: epithelial to mesenchymal transition; TNM: tumor/node/metastasis.
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4.1.1. HOTAIR
One of the most well studied lncRNAs in HCC is the HOX transcript antisense intergenic RNA
(HOTAIR) identified from a custom tilling array of the HOXC locus (12q13.13). HOTAIR represses
transcription in trans acting as a scaffold for at least two distinct histone modification complexes
to the target gene promoters: PRC2 and the lysine-specific demethylase 1 (LSD1)/co-repressor of
RE1-silencing transcription factor (coREST)/REST complex [21,51,117].
Several studies showed that HOTAIR levels are elevated in HCC [82–87], and that its expression
is associated with patients with increased risk of recurrence or metastasis [82,86], poor prognosis [84]
and significantly shorter recurrence-free survival [83]. At the cellular level, HOTAIR is involved
in proliferation, cell motility, viability and invasion, cell cycle progression, apoptosis, autophagy,
and chemotherapeutic sensitivity of cancer cells to cisplatin and doxorubicin [83–88,117–120].
Recently, several studies have revealed novel insights into the functional mechanisms of HOTAIR
in HCC cells. Su et al., demonstrated that HOTAIR expression is regulated by FOXC1 and that the
oncogenic activity of HOTAIR is in part based on its sponging of miR-1 [85]. Indeed, miRNA sponging
appears to be a general mechanism of HOTAIR, as HOTAIR also targets miR-218, resulting in increased
cell viability, cell cycle upregulation, and tumorigenicity [120]. In primary human HCC specimens,
HOTAIR was shown to be concordantly upregulated with the oncogene BMI1, which is a target of
miR-218. Interestingly, HOTAIR silencing activates the main BMI1 downstream targets P16(Ink4a) and
P14(ARF), by enhancing miR-218 and inhibiting BMI1 expression, thus resulting in the suppression of
tumorigenesis in HCC [120].
HOTAIR also binds to transcripts and proteins. An integrated transcriptomic and quantitative
proteomic analysis revealed that a total of 673 transcripts and 293 proteins are regulated by
HOTAIR [121]. The analysis also showed that HOTAIR controls cell proliferation by regulating opioid
growth factor receptor (OGFR) expression [121]. Cell proliferation in HCC could also be driven
by HOTAIR-dependent regulation of cell cycle via STAT3 signaling [119]. Besides cell proliferation,
HOTAIR has also been shown to be involved in the regulation of pluripotency. In fact, the binding
of HOTAIR with the DDX5-PRC2 complex in the HBx-expressing hepatocytes 4pX-1 regulates the
transcription of the epithelial cell adhesion marker EpCAM and pluripotency genes Nanog, Oct4,
and Sox2 [122]. Emerging evidence also suggests a novel relationship between HOTAIR and glucose
metabolism in HCC cells by upregulating glucose transporter isoform 1 (GLUT1) and activating the
mammalian target of rapamycin (mTOR) signaling pathway [87].
4.1.2. HOTTIP
Among the lncRNAs dysregulated in HCC, HOTTIP deserves a special mention. This 3764
nucleotide RNA molecule is transcribed 330 base pairs upstream of the HOXA locus on chromosome
7p15.2. It could be considered a classical eRNA acting in cis. Mechanistically, it is a clear example of
an lncRNA that serves as a scaffold for chromatin remodeling complexes. Wang et al. [25] showed
that, similar to HOXA genes, HOTTIP is normally expressed at a very low level in distal/posterior
anatomical sites and it is implicated in the transcriptional regulation of the HOXA locus. Briefly,
they demonstrated that in distal fibroblast (foreskin) cells, HOTTIP binds to the WDR5-MLL complex
and is able to position the complex in close proximity to the downstream HOXA genes by chromosomal
looping, thus inducing their H3K4me3 and H3K4me4 methylation and subsequent transcriptional
activation [25].
HOTTIP has been found dysregulated in several types of cancers. Its role in human carcinogenesis
was firstly revealed in HCC [89] and has since been described in colorectal [123,124], gastric [125–127],
pancreatic [128,129], and lung cancers [130], as well as in osteosarcoma [131] and glioma [132].
The results from these studies were collectively analyzed in three parallel meta-analyses, all of which
clearly showed that the high expression of HOTTIP correlates with shorter overall survival, higher
tumor grade and poor prognosis [133–135].
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Quagliata et al. [89] reported the upregulation of the HOTTIP transcript in 52 snap-frozen HCC
biopsies from therapy naive patients. The authors reported a higher expression of HOTTIP in
non-neoplastic liver disease (excluding steatosis) when compared to normal tissue. For the first
time, HOTTIP expression was found to be correlated with tumor progression and metastasis formation,
as well as with overall patient survival, thus proposing HOTTIP as a possible prognostic factor for
HCC [89]. Furthermore, the study showed that HOTTIP positively regulates HOXA13 expression
in HCC cell lines and that its upregulation induces proliferation in vitro. Similarly, Tsang et al.,
also reported increased HOTTIP expression in HCC, highlighting the progressive upregulation of
HOTTIP from cirrhotic tissue to pre-neoplastic lesion to early stage HCC [90]. They further confirmed
the oncogenic potential of HOTTIP in a mouse xenograft model and reported that HOTTIP can be
regulated by miRNA, specifically by miR-125b [90].
The role of miRNAs in HOTTIP regulation has been further unraveled by Ge et al., who observed
a negative correlation between HOTTIP and miR-192/204 in 48 tumor-normal paired liver samples
and showed that HOTTIP expression can be regulated by miR-192 and miR-204 via the canonical
Argonaute2 mediated interference (siRNA) [136]. Specifically, the authors showed that miR-192 and
miR-204 directly suppress HOTTIP in vitro and further identified the GLS1 gene, which plays a critical
role in glutaminolysis and tumorigenesis, as a putative downstream target of HOTTIP. Ge et al.,
thus proposed a novel mechanism of action for HOTTIP, in which it explicates its oncogenic potential
by directly upregulating glutaminolysis in HCC cells and promoting cancer cell proliferation in a time
and dose dependent manner [136].
Despite the extensive functional studies, there remains a lot to be discovered in the functional
relevance of HOTTIP in HCC. For instance, a meta-analysis of 393 HCC from the TCGA study revealed
an association between HOTTIP expression and the genes that are involved in the PPAR signaling
pathway, opening the doors to the further characterization of the role of HOTTIP in HCC [137].
4.1.3. MALAT1
MALAT1 is transcribed from chromosome 11q1 and was originally identified as a prognostic
marker for metastasis and patient survival in non-small cell lung carcinoma [99]. Subsequent
studies have shown that MALAT1 is aberrantly up-regulated in various tumor entities [138,139].
Its upregulation promotes tumor growth and metastasis through a variety of mechanisms, including
regulating gene expression by recruiting or regulating the level of serine/arginine-rich protein (SR)
family members that are involved in alternative splicing [58,140,141] or binding to active genomic
sites [34]. High expression of MALAT1 has been associated with high grade, metastasis, and poor
prognosis of cancer patients [141,142].
MALAT1, together with NEAT1, is one of the few lncRNAs to be described as frequently mutated
in HCC leading to the dysregulation of gene expression and regulatory functions [143]. In HCC,
Lai et al., reported that MALAT1 is overexpressed both in vitro and in vivo [100]. Patients with high
expression level of MALAT1, associated with elevated levels of α-fetoprotein (AFP), have a significantly
increased risk of tumor recurrence after liver transplantation [100]. Mechanistically, what is known
about MALAT1 regulation in HCC is that it is transcriptionally regulated by HIF-2α, forming a positive
feedback loop involved in the malignant transformation induced by arsenite [144]. It has also been
suggested that MALAT1 could be regulated by the transcription factor, specificity proteins 1 and 3
(Sp1/3) [145].
The mechanisms by which MALAT1 promotes cell invasion, migration, growth, motility and
metastasis in HCC have been shown to be principally related to its ability to bind to miRNAs and
function as a sponge, capturing miRNA and regulating their activities. There are at least two miR-216b
binding sites in MALAT1 and the HIF-2α-MALAT1-miR-216b axis regulates multidrug resistance of
HCC cells by modulating autophagy [146]. By sponging and competitive binding to miR-204, MALAT1
releases the miR-204-mediated suppression of sirtuin 1, which in turn promotes HCC migration and
invasion [63]. Furthermore, the sponging of miR-146b-5p by MALAT1 has also been shown to promote
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tumor growth and metastasis and has been associated with poor survival in HCC patients [147].
Another example is the binding of miR-143-3p, which in turn, regulates the tumor suppressor gene
ZEB1 [148]. Recently, MALAT1 has been found to act as a ceRNA for miR-195 that is no longer able to
suppress its downstream target EGFR [149].
A high-throughput strategy by combining RNA pull-down, quantitative proteomics,
bioinformatics, and experimental validation has resulted in the identification of interacting protein
partners of MALAT1 in HCC. Indeed, the interactome of MALAT1 involves ribosomal proteins
and proteins critical in RNA processing, gene transcription, protein degradation, and metabolism
regulation [150]. The interaction between MALAT1 and the depleted in breast cancer 1 protein (DBC1)
was further validated and characterized, revealing a novel mechanism by which MALAT1 regulates
p53 activity through the interaction with DBC1 [150].
4.1.4. NEAT1
LncRNA nuclear enriched abundant transcript 1 (NEAT1) is so called because of its peculiar
and exclusive localization in the sub-nuclear compartment paraspeckle [33]. In this compartment,
NEAT1 can modulate gene expression by retaining mRNA molecules in the nucleus and by mRNA
editing [151]. Of note, NEAT1 is genomically in close proximity to MALAT1 and both are frequently
mutated in HCC [143]. NEAT1 has also been reported to co-localize with MALAT1 on active chromatin
sites where both interact with proteins that are resident in the nuclear bodies [34]. Despite its emerging
relevance in the regulation of gene expression, studies on the role of NEAT1 in human malignancies
have remained limited so far. It is known that NEAT1 is a crucial regulator in several cancers and acts
as a pivotal player in tumorigenesis and metastasis of HCC. Guo et al., firstly reported the clinical
relevance of NEAT1 overexpression in HCC tissues and its association with several clinical features
such as the number and size of tumor nodes, metastasis formation, TNM stage, vascular invasion, and
tumor cell infiltration [109].
The overexpression and relevance of NEAT1 in HCC tissues and cell lines have been further
confirmed in several recent studies aiming to delineate the functional mechanisms of NEAT1 in HCC
pathogenesis [108,110,111]. These studies have shown that NEAT1 may act both as a miRNA sponge
and as a protein-binding competitor. The ability of NEAT1 in sponging miRNAs was first described
by Fang et al. [108], who reported NEAT1 overexpression in HCC tissues, as well as its negative
correlation with miR-129-5p expression. They also proposed a mechanism of action involving the
miR-129-5p, valosin-containing protein (VCP) and IkB axis. Other studies have described similar
negative correlations with miR-613 [111] and miR-485 [64]. Interestingly, Zhang et al., showed that by
acting as ceRNA for miR-485, NEAT1 is indeed able to enhance STAT3 expression in HCC [64].
The function of NEAT1 is not restricted to miRNA sponging, as it has also been reported to bind
to and compete for the assembling of protein complexes. Mang et al., for instance, demonstrated that
NEAT1 forms a protein complex with the splicing factor U2AF65, thus regulating the heterogeneous
nuclear ribonucleoprotein hnRNP A2 expression [110]. hnRNP A2 is also an essential splicing factor
that promotes cell proliferation and invasion, and correlates with poor outcome in HCC patients.
Since hnRNP A2 is normally inhibited by U2AF65, the authors proposed a mechanism by which
NEAT1 may favor HCC development by sequestrating U2AF65 and releasing hnRNP A2 activity [110].
Last but not least, two independent studies have associated NEAT1 with epithelial-to-
mesenchymal transition (EMT) [112,152]. In a study using breast cancer tissues and cell lines,
Choudhry et al., identified NEAT1 as a new transcriptional target of HIF-2α and described its ability
to induce paraspeckle formation under hypoxic condition [152]. Similarly, Zheng et al., found that
the overexpression of HIF-2α upregulates the level of NEAT1, thus promoting EMT and metastasis in
hepatoma cell lines [112].
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4.1.5. H19
H19 is transcribed from the critical imprinted locus IGF2/H19 on chromosome 11p15.5 and it
was the first lncRNA identified [153]. In most normal adult tissues, only the paternal allele of IGF2 is
expressed, whereas the maternal imprinted allele of H19 is usually expressed at high levels during
embryonic development, but is rapidly repressed in most tissues after childbirth [154]. H19 is involved
in transcription regulation by binding to hnRNP U and disrupting the hnRNP U-actin complex,
thus inhibiting the phosphorylation of the RNA Pol II C-terminal domain at Ser5 and consequently
preventing RNA Pol II-mediated transcription [155]. Many studies have shown a strong association
between H19 expression and dysregulated imprinting of the IGF2/H19 locus with carcinogenesis in
several types of cancer, including HCC [156–160].
H19 is also a ceRNA that acts as a sponge for miRNAs ([161] and references therein). For example,
in breast cancer H19 regulates EMT and mesenchymal-epithelial transition (MET) by differentially
acting as a sponge for miR-200b/b and let-7b [162].
Recently, a new role of the H19-IGF2 axis in regulating hepatocyte proliferation has been
described in mice. It was demonstrated that H19 and Igf2 are negatively regulated by PHB1 and
CTCF, which cooperatively bind the imprinting control region (ICR) of the Igf2/H19 locus [79].
Whether H19 acts as an oncogene or as a tumor suppressor gene is controversial. Zhang et al. [163]
demonstrated that H19, in association with hnRNP U/PCAF/RNAPol II, activates miR-200 family
by increasing histone acetylation, thus contributing the suppression of EMT and tumor metastasis.
Moreover, they showed that H19 is significantly downregulated in intratumoral (T) HCC tissues
compared with peritumoral tissues (L), and that patients with low T/L ratio of H19 were linked to poor
prognosis [163]. H19 is also a precursor for miR-675 and both were found downregulated in HCC cells
and their downregulation promotes migration and invasion of HCC via the AKT/GSK-3beta/Cdc25A
signaling pathway [77]. On the contrary, Yang et al., demonstrated that H19 is overexpressed in
HBV-infected patients and is a risk factor for reduced disease-free survival and increased tumor
aggressiveness in HCC patients [78].
4.1.6. Other lncRNAs Dysregulated in HCC
Highly up-regulated in liver cancer (HULC) is a 500 nucleotide lncRNA on chromosome 6p24.3 and it
was first identified as one of the most upregulated genes in HCC [93]. It was described to modulate the
deregulation of lipid metabolism in HCC through a signaling pathway involving miR-9, PPARA, and
ACSL1 [96]. It was also shown to promote hepatocarcinogenesis by perturbing the circadian rhythm
through upregulating circadian oscillator CLOCK in hepatoma cells [164]. Recently, HULC has been
described to regulate several signaling pathways by acting as a sponge for miRNAs. For instance, it
promotes tumor progression and metastasis through the miR-200a-3p/ZEB1 signaling pathway [92]
and promotes tumor angiogenesis in liver cancer through miR-107/E2F1/SPHK1 signaling [97]. HULC
also plays an epigenetic role by enhancing the level of ubiquitin-specific peptidase 22 (USP22) and
stabilizing the COX2 protein [94]. Finally, together with USP22/Sirt1, HULC attenuates the sensitivity
of HCC cells to chemotherapeutic agents by inducing “protective autophagy” [98].
Maternally Expressed Gene 3 (MEG3) encodes a tumor suppressor lncRNA that is expressed in
many normal tissues [165]. Methylation of MEG3 promoter and its marked downregulation have been
reported in HCC cell lines and tissues [102,103]. MEG3 expression negatively correlates with tumor
size and TNM stage, thus acting as a potential prognostic biomarker [107]. The forced expression of
MEG3 in HCC cells significantly reduces both anchorage-dependent and -independent cell growth,
and induces apoptosis [103], at least partially via the accumulation of p53 [107]. Indeed, it has been
demonstrated that MEG3 is able to interact with the p53 DNA binding domain [106], thus enhancing
its stability and transcriptional activity.
LincRNA-Ubiquitin-Fold Modifier Conjugating Enzyme 1 (lincRNA-UFC1) is also upregulated in
HCC tissues and its expression associates with tumor size, stage, and patient outcome. Its expression in
HCC cells promotes cell proliferation and cell-cycle progression and inhibits apoptosis [166]. Levels of
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lincRNA-UFC1 were described to correlate with those of ß-catenin in HCC tissues through a mechanism
that involves the stabilization of the HuR protein (encoded by ELAVL1) by directly binding with the
mRNA [166].
Urothelial carcinoma-associated 1 (UCA1) was reported to be markedly upregulated in HCC tissues
and its expression in HCC is positively associated with tumor size, vascular invasion, TNM stage,
metastasis, and postoperative survival [114,115]. Moreover, higher levels of UCA1 were also detected
in serum of HCC patients [167] and are associated with higher grade, larger tumor size, higher TNM
stage, and vascular invasion, acting as an independent unfavorable prognostic factor for HCC [113].
Acting as a miRNA sponge, UCA1 can either promote EMT [114] or activate the ERK signaling pathway
in HCC [115]. Of note for hepatocarcinogenesis associated with HBV infection, UCA1 was found to be
frequently upregulated in HBx-positive tissues and was shown to be upregulated by HBx in hepatoma
cells, thus promoting cell growth by facilitating G1/S transition through CDK2 [168].
LncRNA-activated by TGF-β (lncRNA-ATB) is significantly upregulated in HCC tissues and
metastasis, and its expression is associated with poor prognosis [169,170]. At the molecular level, it has
been shown that lncRNA-ATB can promote the invasion-metastasis cascade, either by inducing EMT
through the upregulation of ZEB1 and ZEB2 or by binding IL-11 mRNA and thus triggering STAT3
signaling [170]. These findings suggest that lncRNA-ATB predisposes HCC patients to metastasis and
may potentially serve as a target for anti-metastatic therapies.
High Expression In HCC (HEIH) is another lncRNA whose high expression levels in HBV-related
HCC were found to be significantly associated with recurrence and it was considered as an independent
prognostic factor for survival. In patients with HCV-related HCC, HEIH expression in serum and
exosomes is increased, but the ratio of HEIH expression in serum versus exosomes is decreased
compared to patients with combined hepatocellular cholangiocarcinoma [81]. It was also described to
play a key role in G0/G1 arrest and the same authors demonstrated that HEIH binds the enhancer of
zeste homolog 2 (EZH2) factor inducing the repression of EZH2 target genes [80].
PCNA Antisense RNA 1 (PCNA-AS1) acts as a scaffold for mRNA molecules and was found
significantly upregulated in HCC. Indeed, one of the roles of PCNA-AS1 is the regulation of PCNA
mRNA stability [171].
5. Putative Diagnostic and Prognostic lncRNAs in HCC
The identification of lncRNAs whose expression levels correlated with clinicopathological
characteristics of patients led to many studies of their diagnostic and/or prognostic potential in
HCC tissues and in liquid biopsies (Figure 3).
For instance, UCA1 levels in HCC tissues [114,115] and in serum [113] were associated with high
tumor grade, large tumor size, positive vascular invasion, and advanced TNM stage and may be
an independent prognostic indicator [113]. Similarly, high levels of MALAT1 were associated with
reduced disease-free survival in patients after liver transplantation [100]. The association between
MALAT1 and prognosis appears to extend to plasma, with increased levels of MALAT1 correlating
with liver damage and predicting progression to HCC [172]. Interestingly, it has also been reported that
germline variants of MALAT1 and HULC may be associated with a decreased risk of HBV-associated
HCC in the Chinese population [173].
Int. J. Mol. Sci. 2018, 19, 682 13 of 25
Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  12 of 25 
 
in serum of HCC patients [167] and are associated with higher grade, larger tumor size, higher TNM 
stage, and vascular invasion, acting as an independent unfavorable prognostic factor for HCC [113]. 
Acting as a miRNA sponge, UCA1 can either promote EMT [114] or activate the ERK signaling 
pathway in HCC [115]. Of note for hepatocarcinogenesis associated with HBV infection, UCA1 was 
found to be frequently upregulated in HBx-positive tissues and was shown to be upregulated by HBx 
in hepatoma cells, thus promoting cell growth by facilitating G1/S transition through CDK2 [168]. 
LncRNA-activated by TGF-β (lncRNA-ATB) is significantly upregulated in HCC tissues and 
metastasis, and its expression is associated with poor prognosis [169,170]. At the molecular level, it 
has been shown that lncRNA-ATB can promote the invasion-metastasis cascade, either by inducing 
EMT through the upregulation of ZEB1 and ZEB2 or by binding IL-11 mRNA and thus triggering 
STAT3 signaling [170]. These findings suggest that lncRNA-ATB predisposes HCC patients to 
metastasis and may potentially serve as a target for anti-metastatic therapies. 
High Expression in HCC (HEIH) is another lncRNA whose high expression levels in HBV-related 
HCC were found to be significantly associated with recurrence and it was considered as an 
independent prognostic factor for survival. In patients with HCV-related HCC, HEIH expression in 
serum and exosomes is increased, but the ratio of HEIH expression in serum versus exosomes is 
decreased compared to patients with combined hepatocellular cholangiocarcinoma [81]. It was also 
described to play a key role in G0/G1 arrest and the same authors demonstrated that HEIH binds the 
enhancer of zeste homolog 2 (EZH2) factor inducing the repression of EZH2 target genes [80]. 
PCNA Antisense RNA 1 (PCNA-AS1) acts as a scaffold for mRNA molecules and was found 
significantly upregulated in HCC. Indeed, one of the roles of PCNA-AS1 is the regulation of PCNA 
mRNA stability [171]. 
5. Putative Diagnostic and Prognostic lncRNAs in HCC 
The identification of lncRNAs whose expression levels correlated with clinicopathological 
characteristics of patients led to many studies of their diagnostic and/or prognostic potential in HCC 
tissues and in liquid biopsies (Figure 3). 
 
Figure 3. Diagnostic/prognostic and therapeutic potentials of lncRNAs. LncRNAs isolated from liquid 
biopsies or tissues could be analyzed at the sequence or expression levels and may serve as potential 
biomarkers for HCC diagnosis, prognosis and therapy response prediction. LncRNAs may also be 
targeted for therapeutic interventions by silencing their expression using canonical Argonaute2 
mediated interference (siRNA) molecules or antisense oligonucleotides (ASO), by blocking the 
interactions with DNA, RNA, or proteins using small synthetic molecules or by CRISPR/Cas9 editing. 
For instance, UCA1 levels in HCC tissues [114,115] and in serum [113] were associated with high 
tumor grade, large tumor size, positive vascular invasion, and advanced TNM stage and may be an 
independent prognostic indicator [113]. Similarly, high levels of MALAT1 were associated with 
Figure 3. Diagnostic/prognostic and therapeutic potentials of lncRNAs. LncRNAs isolated from
liquid biopsies or tissues could be analyzed at the sequence or expression levels and may serve as
potential biomarkers for HCC diagnosis, prognosis and therapy response prediction. LncRNAs may
also be targeted for therapeutic interventions by silencing their expression using canonical Argonaute2
mediated interference (siRNA) molecules or antisense oligonucleotides (ASO), by blocking the
interactions with DNA, RNA, or proteins using small synthetic molecules or by CRISPR/Cas9 editing.
Besides UCA1, MALAT1, and well-known lncRNAs, such as HOTAIR [82,84], HULC [92,93,174],
a number of other lncRNAs whose expression was associated with disease stage and/or other
clinicopathologic parameters have also been described. Recently, Yang et al., identified HAND2-AS1
as a potential biomarker for HCC tumorigenesis and metastasis [75]. Similarly, high expression
levels of CASC15 [175], CYTOR (also known as Linc00152) [174], HANR [176], ICR (ICAM-1-Related
ncRNA) [177], linc-UFC1 [166], lncRNA-ATB [170], lncSHRG [178], MVIH [179], PANDAR [180],
PCAT14 [181], SNHG6 [182], SNHG20 [183], TINCR [184], TMCC1-AS1 [72], UBE2CP3 [185],
WRAP53 [116]], ZEB1-AS1 [186], as well as the downregulation of LOC728290 [187], GAS5 [188],
DILC [189], or WT1-AS [190], have been variably shown to be correlated with clinical severity,
aggressive pathological features, metastasis, and/or poor outcome in HCC patients (Table S1).
However, it should be noted that given that lncRNA is a fairly young research field, many of these
associations have thus far been reported in single studies. Moreover, these studies differ substantially
in their cohort sizes, etiologies and detection methods, and therefore the clinical utility for many of
these lncRNAs remains to be validated and further tested in independent studies.
6. Therapeutic Potential of lncRNA in HCC
Tumor suppressor genes are notoriously difficult to target therapeutically, since a gain of function
is difficult to achieve using current generations of therapeutic options [191]. In this context, the ability
for lncRNAs to variably up- or down-regulate coding genes makes them attractive therapeutic targets.
In particular, one possibility is the modulation of cis-acting lncRNAs, which may result in specific,
endogenous alteration of the expression level of their target genes [192]. Several approaches have been
proposed to target the various aspects of lncRNA mechanisms of action (Table 2). It should, however,
be noted that lncRNAs as therapeutics is currently largely speculative based on the biological functions
of lncRNAs and data observed in in vitro/in vivo studies. The development of therapeutic agents
against lncRNAs is still far from clinical application.
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Table 2. Therapeutic use of lncRNAs in HCC.
lncRNA Molecular Strategy Reference
Ad5-AlncRNA Overexpressed to target miRNAs [193]
DANCR Silenced by shRNA [194]
lncRNA-ATB Silenced by siRNA molecules [195]
MALAT1 Silenced by antisense oligonucleotides (ASO) [196]
MALAT1 Silenced by CRISPR/Cas9 [197]
The first proposed approaches directly target lncRNAs to induce their degradation or
destabilization. These methods include RNA interference mediated gene silencing and antisense
oligonucleotides (ASO). For example, the delivery of siRNA molecules using ultrasound-targeted
microbubble destruction was used to silence lncRNA-ATB, suppressing HCC migration and invasion
in vitro [195]. Some in vivo evidence of successful inhibition of MALAT1 and metastasis by injecting
ASO into subcutaneous tumors of nude mice has been reported for lung cancer cells [196].
An alternative therapeutic approach could be to block the interactions of lncRNA with DNA,
RNA, or proteins using antagonistic sequences or small synthetic molecules that cover the lncRNA
binding sites [198]. In addition, gene therapy represents an emerging and very promising strategy.
Indeed, it was recently shown that the CRISPR/Cas9 technology could be successfully used to target
an enhancer and exonic fragment of MALAT1 in human cells [197].
In view of their miRNA binding capacity, lncRNAs can be used not only as targets but also to target
miRNAs involved in HCC. For example, the miRNAs miR-21, miR-153, miR-216a, miR-217, miR-494
and miR-10a-5p have been shown to be upregulated in sorafenib-resistant cells and to participate
in the mechanisms that are underlying sorafenib resistance [193]. The simultaneous targeting of
these miRNAs using an artificial lncRNA expressed by an adenoviral vector (Ad5-AlncRNA) inhibits
proliferation and induces apoptosis of sorafenib-resistant cells and enhances the effects of sorafenib
in vitro and in vivo [193]. This may represent a potential strategy to overcome sorafenib resistance in
the treatment of HCC.
7. Conclusions
Whole-transcriptome analyses are beginning to provide important insights into the biological
and clinical relevance of lncRNAs in cancer. When compared to protein-coding genes, our knowledge
in lncRNAs is in its infancy and many, many more studies are required to define which lncRNAs
are genuinely critical in hepatocarcinogenesis. For HCC, the lack of molecular targets may benefit
from exploiting lncRNAs as therapeutic targets. Future development in this area will be particularly
exciting to increase the number of treatment options.
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Abbreviations
LncRNA Long non-Coding RNA
HCC Hepatocellular Carcinoma
HBV Hepatitis B Virus
HCV Hepatitis C Virus
TCGA The Cancer Genome Atlas
Sno-RNA Small nuclear RNA
CircRNA Circular Intronic Long non-Coding RNA
SnolncRNA Small Nuclear Long non-Coding RNA
NAT Natural Antisense Transcript
LincRNA Long intergenic RNA
PancRNA Promoter Associated non-Coding RNA
CeRNA Competing Endogenous RNA
EMT Epithelial to Mesenchymal Transition
TNM Tumor Node Metastasis
eRNA Enhancer RNA
siRNA Small interference RNA
MET Mesenchimal to Epithelial Transition
ASO Antisense Oligonucleotides
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